Skip to main content
GANX logo

GANX

Gain Therapeutics, Inc.
$1.81 +0.00 (+0.00%) At close · Jul 7
Market Cap
$77.20M
Shares
42,654,038

Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.

Revenue
$55.18K -60.6%
FY2023 Revenue FY2020–FY2023
Net Income
-$20.16M +1.2%
FY2025 Net Income FY2020–FY2025
Operating Margin
-40328.26% -27640.2pp
FY2023 Operating Margin FY2020–FY2023
Diluted EPS
-$0.61 +31.5%
FY2025 Diluted EPS FY2020–FY2025
Operating Cash Flow
-$18.47M +2.2%
FY2025 Operating Cash Flow FY2020–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item TTM FY2025 FY2024 FY2023 FY2022 FY2021 FY2020
$55.18K $140.11K $164.99K $28.88K
$411.51K $494.23K $375.36K $12.5K $3637
$10.72M $10.21M $10.79M $11.52M $8.38M $7.16M $2.26M
$8.98M $8.5M $9.56M $10.79M $9.54M $6.83M $1.25M
$94.05K $84.07K $83.58K $64.17K $15.48K $9592
$19.69M $18.71M $20.35M $22.31M $17.92M $13.99M $3.51M
-$19.69M -$18.71M -$20.35M -$22.25M -$17.78M -$13.83M -$3.48M
-40328.26% -12688.1% -8379.8% -12047.54%
-$18.62M -$20.27M -$22.17M -$17.71M -$13.81M -$3.47M
-$20.3M -$19.3M -$19.87M -$22.19M -$17.5M -$13.89M -$3.57M
$943.68K $861.12K $536.82K $79.28K $92.98K $4008 $5386
-$21.24M -$20.16M -$20.41M -$22.27M -$17.59M -$13.89M -$3.58M
-40354.33% -12555.13% -8418.86% -12387.67%
-$20.12M -$19.14M -$20.91M -$22.06M -$17.46M -$13.83M -$3.65M
USD/shares -$0.61 -$0.89 -$1.71 -$1.48 -$1.37 -$1.33
USD/shares -$0.61 -$0.89 -$1.71 -$1.48 -$1.37 -$1.33
shares 32.97M 22.88M 13.01M 11.88M 10.17M 2.68M
shares 32.97M 22.88M 13.01M 11.88M 10.17M 2.68M
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Key facts CIK 1819411 CUSIP 36269B105 Visit website Investor relations